Pfizer’s billion-dollar Celebrex patent loss has Mylan, Actavis revving up generics

Tracy Staton One of Pfizer's top-selling products is suddenly vulnerable to generic competition 18 months earlier than expected. A U.S. court nixed a key Celebrex patent, putting ...

Allergan rides high on patent backing for key drugs Lumigan and Restasis

Carly Helfand Patent-cliff worries have been weighing on Allergan as of late, but a Texas judge has allayed some of those concerns–at least for now. That judge upheld ...

AstraZeneca’s Nexium gets a Korean competitor to chase it over the patent cliff

Carly Helfand The difference between magnesium salt and strontium salt may be enough to threaten U.S. sales of AstraZeneca's blockbuster Nexium–starting now. Reports say South ...

Idenix fires off a shot in patent battle over Gilead’s sofosbuvir

Damian Garde As Gilead nears a virtually guaranteed FDA approval for the hepatitis C-fighting sofosbuvir, the biotech is facing intellectual property challenges from a bevy of competitors, ...

U.S. access group aims to block Indian patent for Gilead’s hot hep C drug

Tracy Staton Gilead Sciences' new hepatitis C drug sofosbuvir won preliminary backing from European regulators on Friday, with marketing approval expected to follow soon. The FDA ...

Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly

barbara.lempert Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly First-in-class antipsychotic therapy for Schizophrenia and Bipolar Disorders London, UK, 13 ...

Immunomedics Awarded Key Patent for TROP-2 Antibody

barbara.lempert MORRIS PLAINS, N.J., Nov. 5, 2013 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal ...

Mylan Confirms First-to-File Patent Challenge Relating to Uloric

mia.burns -Expects to be eligible for 180 days of marketing exclusivity- PITTSBURGH, Nov. 1, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today confirmed that its U.S.-based ...

StemCells, Inc. Acquires Seminal Neural Stem Cell Patent Portfolio

barbara.lempert NEWARK, Calif., Oct. 29, 2013 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) today announced the acquisition of a portfolio of issued US and Canadian patents ...

Top 10 Drug Patent Losses of 2014

Tracy Staton FiercePharma News

Aegis Awarded Its First Patent for Non-Invasive Delivery of a Protein Drug to the Central Nervous System (CNS)

barbara.lempert SAN DIEGO, CA October 9, 2013/MarketWired– Aegis Therapeutics LLC announced today that it has been awarded its first patent for non-invasive delivery of a protein ...

UPDATED: Merck demand triggers expanding patent war with Gilead over sofosbuvir

John Carroll Gilead is rolling out its big legal guns to defend its control of the experimental hepatitis C drug sofosbuvir, one of the most valuable therapies in the industry's ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS